ischemia

The MGuard stent shows a trend toward reduced mortality in PCI

Original title: Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction. Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial. Reference: DariuszDudek et al. CircCardiovascInterv. 2015 Feb;8(2).   The MGuard is a micronet mesh-covered stent designed to reduce distal embolization in the context of ST elevation myocardial infarction. In the MASTER study...

Net clinical benefit of bivalirudin in STEMI patients

Original title: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials. Reference: Stone GW et al. J Am CollCardiol. 2015 Jan 6;65(1):27-38. The HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) that included 3602 STEMI patients undergoing...

Never ending controversy over the duration of post DES dual antiplatelet therapy

Original title: Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month – Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial. Reference: Antonio Colombo et al. J Am CollCardiol. 2014 Nov 18;64(20):2086-97. The optimal duration of dual antiplatelet therapy after second-generation DES implantation is still debated and apparently will remain controversial for some time. The aim of this...

Despite the evidence, visual estimation continues to dominate the decision on intermediate lesions

Original title: Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions. Results of the International Survey on Interventional Strategy. Reference: Gabor G. Toth et al. CircCardiovascInterv. 2014. Epubahead of print.   Measurement of fractional flow reserve (FFR) is recommended by the guidelines and supported by evidence in intermediate lesions when not any proof of ischemia is available...

PCI Superior to Optimal Medical Treatment in Patients with Ischemic Cardiomyopathy

Original title: Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease. The FAME 2 Trial Investigators. Reference: Bernard De Bruyne et al. N Engl J Med 2014;371:1208-17. The FAME 2 and the COURAGE studies tested similar hypothesis, only in the first study PCI was guided by fractional flow reserve (FFR) in addition to an angiography. The study hypothesis...

Thrombosis with bioresorbable scaffolds: the story of DES all over again?

Original title: Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Reference: Capodanno D et al. EuroIntervention. 2014 Jul 18. Epub ahead of print   The GHOST-EU registry, that included 1189 patients from 10 European centers between 2011 and 2014, is now the largest registry...

Benefits at 5 years of routine invasive strategy in Non-ST-Elevation Acute Coronary Syndromes

Original title: Impact of an invasive strategy on five years outcomein men and women with Non-ST-Elevation Acute Coronary Syndromes. Reference: Joakim Alfredsson et al. Am Heart J. 2014;Epub ahead of print.   This meta-analysis included patients with non-ST-elevation acute coronary syndrome (NSTE ACS) from randomized studies FRISC II, ICTUS and RITA 3 and compared the routine invasive strategy...

Severe coronary calcification is a predictor of coronary events in acute coronary syndromes

Original title: Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Pooled Analysis From the HORIZONS and ACUITY Trials. Reference: Philippe Généreux, et al. J Am Coll Cardiol 2014;63:1845-54 Calcification of the arteries has always been a challenge and a generator of problems during coronary angioplasty, but its impact on acute coronary syndromes has not...

Blush reduction in a not responsible vessel is a prognostic marker in those receiving angioplasty in the culprit vessel.

Original title: Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneos Coronary OIntervention for Acute Coronary Síndromes. Analysis From ACUITY Trial. Reference: Alexandra Lansky, et al. JAAC Cardiovascular Intervention 2014,7:266-275 In Non ST elevation Acute Coronary Syndrome (NSTE-ACS) is demonstrated that revascularization of the culprit vessel is beneficial, but strategy it is not yet clear...

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial. Reference: Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75.   DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to...

Top